Olgu Sunumu

Management and outcomes of spontaneous rectus sheath hematoma with apixaban

Cilt: 6 Sayı: 3 1 Aralık 2021
PDF İndir
TR EN

Management and outcomes of spontaneous rectus sheath hematoma with apixaban

Öz

Introduction: Apixaban is a comparatively newly used oral factor Xa inhibitor, which seems to be safer, compared to both aspirin and warfarin in terms of bleeding. There are very few reported apixaban-related side effects in the literature, and one of them is rectus sheath hematoma. Case Report: A 78-year-old female patient was admitted to the emergency service of our hospital with complaints of abdominal pain, cough, and dyspnea, and she also complained of ecchymosis on her abdominal region. Her medical history revealed that she had hypertension, asthma, coronary artery disease, and nonvalvular atrial fibrillation. The patient had been on apixaban for 16 months for nonvalvular atrial fibrillation. Abdominal ultrasonography and computed tomography revealed a rectus sheath hematoma of nearly 30x40 mm in size. The patient managed conservatively, but she died due to respiratory failure. Conclusion: Clinicians should be aware of spontaneous rectus sheath hematoma in apixaban using patients with abdominal pain. Although apixaban is a safe anticoagulant drug, it may cause complications such as spontaneous bleeding.

Anahtar Kelimeler

Teşekkür

The authors would like to thank Duygu G. Sevim for her assistance in the editing of this article.

Kaynakça

  1. 1. Administration DFFadpSSMFaD (2013). [Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/.
  2. 2. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015;79(5):838-46.
  3. 3. Administration DFFadpSSMFaD (2018). [Available from: https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm606681.htm.
  4. 4. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008;6(5):820-9.
  5. 5. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014;63(20):2141-7.
  6. 6. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17.
  7. 7. Osinbowale O, Bartholomew JR. Rectus sheath hematoma. Vasc Med 2008;13(4):275-9.
  8. 8. Sheth HS, Kumar R, DiNella J, Janov C, Kaldas H, Smith RE. Evaluation of Risk Factors for Rectus Sheath Hematoma. Clin Appl Thromb Hemost 2016;22(3):292-6.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Olgu Sunumu

Yayımlanma Tarihi

1 Aralık 2021

Gönderilme Tarihi

15 Eylül 2021

Kabul Tarihi

29 Kasım 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 6 Sayı: 3

Kaynak Göster

APA
Sevim, Y., & Çarkıt, S. (2021). Management and outcomes of spontaneous rectus sheath hematoma with apixaban. Journal of Anatolian Medical Research, 6(3), 91-94. https://izlik.org/JA86ND69JK
AMA
1.Sevim Y, Çarkıt S. Management and outcomes of spontaneous rectus sheath hematoma with apixaban. JAMER. 2021;6(3):91-94. https://izlik.org/JA86ND69JK
Chicago
Sevim, Yusuf, ve Sedat Çarkıt. 2021. “Management and outcomes of spontaneous rectus sheath hematoma with apixaban”. Journal of Anatolian Medical Research 6 (3): 91-94. https://izlik.org/JA86ND69JK.
EndNote
Sevim Y, Çarkıt S (01 Aralık 2021) Management and outcomes of spontaneous rectus sheath hematoma with apixaban. Journal of Anatolian Medical Research 6 3 91–94.
IEEE
[1]Y. Sevim ve S. Çarkıt, “Management and outcomes of spontaneous rectus sheath hematoma with apixaban”, JAMER, c. 6, sy 3, ss. 91–94, Ara. 2021, [çevrimiçi]. Erişim adresi: https://izlik.org/JA86ND69JK
ISNAD
Sevim, Yusuf - Çarkıt, Sedat. “Management and outcomes of spontaneous rectus sheath hematoma with apixaban”. Journal of Anatolian Medical Research 6/3 (01 Aralık 2021): 91-94. https://izlik.org/JA86ND69JK.
JAMA
1.Sevim Y, Çarkıt S. Management and outcomes of spontaneous rectus sheath hematoma with apixaban. JAMER. 2021;6:91–94.
MLA
Sevim, Yusuf, ve Sedat Çarkıt. “Management and outcomes of spontaneous rectus sheath hematoma with apixaban”. Journal of Anatolian Medical Research, c. 6, sy 3, Aralık 2021, ss. 91-94, https://izlik.org/JA86ND69JK.
Vancouver
1.Yusuf Sevim, Sedat Çarkıt. Management and outcomes of spontaneous rectus sheath hematoma with apixaban. JAMER [Internet]. 01 Aralık 2021;6(3):91-4. Erişim adresi: https://izlik.org/JA86ND69JK